| Home | Log In | Register | Our Services | My Account | Contact | Help |
ValiRx Plc - Bioscience Innovation (VAL)
Robbie C - 12 May 2013 13:01
Valirx wants to make a structural change in science, namely to engineer a scientific breakthrough into human health and wellbeing, through early detection of disease and therapeutic intervention. Research shows that there is a high demand for new personalised medicines and services that enhance patient care, achieve faster diagnoses, and substantially improve treatment outcomes cost effectively.
Valirx is a growing company with a clear business model. We reduce risk in new product development through a rigorous clinical and commercial due diligence process, selecting drug candidates and technologies with evidence-based potential to address the unmet needs of the market. We aim to maximise returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Valirx management team is a mixture of entrepreneurial scientists and business professionals, all with experience in developing medical life science companies. The team is also experienced at transferring technologies and products into the commercial arena to generate revenue and grow shareholder value.
Latest News - http://www.valirx.com/news
Bullshare
- 18 Nov 2016 10:23
- 17 of 20
Shares Investor Evenings showcase presentations from leading companies bringing them together in one room.
- Directors present their latest plans regarding development and growth
- An opportunity to talk directly to the companies and personally put forward your questions
- The chance to network with other attendees over drinks and canapés - private investors, wealth managers, fund managers and financial institutions
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Tuesday 29th November 2016
Venue:Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Peter Secker, CEO - Bacanora Minerals (BCN) • Giles Clarke, Chairman - Kennedy Ventures (KENV) • Dr. George Morris, Chief Operations Officer - Valirx (VAL) + More to be announced | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
 | Bacanora Minerals Ltd is an explorer and developer of industrial minerals in Mexico with a primary focus on Borates and Llithium. It was incorporated in Alberta, Canada in September 2008 and is listed on the TSX Venture Exchange (ticker = BCN). Although listed in Canada, we are proud to consider ourselves a Mexican Company. The word Bacanora refers to a Mexican agave liquor traditionally distilled in the hills of Sonora with much care and attention. Bacanora Minerals strives to replicate this tradition of skill and dedication to quality in its own operations.
|
 | Kennedy Ventures plc is an investing company listed on AIM, focused on principally, but not exclusively, in the resources sector. The Company has made a first investment in African Tantalum (Pty) Ltd, a Namibian based operation producing tantalite concentrate. In view of the attractive opportunities in tantalum, the Company is likely to initially focus on related projects located in Southern Africa. |
 | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |
Bullshare
- 17 Jan 2018 10:03
- 18 of 20
The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy.
Tuesday 13 February 2018
Venue:Novotel Tower Bridge, London EC3N 2NR, 10 Pepys Street, London, EC3N 2NR
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Dave Mutton, Chief Operating Officer - PrimaryBid • Stewart MacDonald, CFO - Rockhopper Exploration (RKH) • Dr. Satu Vainikka, CEO - Valirx (VAL) + More to be announced | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
 | PrimaryBid the leading online equity funding platform, available on both web and mobile, that enables investors to gain access to placings, fundraisings and IPOs of AIM-listed companies. The platform is open to all investors and is supported by the broking community as a way of accessing, on behalf of their AIM clients seeking capital, the large and active private investor market, as well as institutions. To date almost £37m has been sourced for issuers, via the platform. |
 | Rockhopper Exploration plc ("Rockhopper") is an AIM listed oil and gas exploration company based in the UK with interests in the Falkland Islands. It was established in 2004 with a strategy to invest in and undertake an offshore oil exploration programme. It was floated on AIM in August 2005. Rockhopper holds 40% interests in production licences PL032 and PL033 and, on completion of a farm-in announced in October 2013, 24% stakes in blocks PL004a, PL004b, and PL004c. All of these blocks are operated by Premier Oil. In addition, it has a 3% interest block PL003, operated by Falkland Oil and Gas. In August 2014 Rockhopper completed the takeover of Mediterranean Oil & Gas plc ("MOG"). Through the acquisition of MOG, Rockhopper now holds a portfolio of production, development/appraisal and exploration interests in Italy, Malta and France. |
 | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |
black bird - 06 Feb 2018 12:00 - 19 of 20
ps is rights , more money wanted.
mitzy - 07 Feb 2018 12:30 - 20 of 20
- Page:
- 1
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Follow us on Twitter